

Zoetis Inc. (ZTS) Overweight

Q3 Revenue Growth Impressive, Solid Results Should Calm Concerns

CONCLUSION

Q3 results were in line with expectations highlighted by slightly higher revenues and EPS that met Street estimates. FY13 guidance was narrowed and ZTS highlighted new product approvals, including two branded generic ractopamine products that gives them exposure to the beta-agonist market. While margins were lower than expected, we were impressed with strong revenue growth in the U.S. and international markets. As we expected, livestock product sales increased 11% and companion animal revenues also grew 10%. We expect to hear more about the livestock market recovery, new product launches, and margin expansion opportunities. CC @ 8:30 AM ET, dial-in #: 866-952-1906, ID: ZTSQ313.

- Revenues slightly better. Total revenues increased 8.2% y/y to \$1,103 MM, which was \$33 MM higher than our estimate of \$1,070 MM and \$38 MM higher than consensus of \$1,065 MM. Operationally, revenues increased 9%, which was partially offset by a 1% FX impact.
 - **o** U.S. revenues increased 10.5% y/y to \$495 MM, \$20 MM higher than our estimate of \$475 MM and \$16 MM higher than the StreetAccounts (SA) consensus of \$479 MM.
 - EuAfME revenues increased 12.0% y/y to \$270 MM, which was \$19 MM higher than our estimate of \$251 MM and \$28 MM higher than SA consensus of \$242 MM. Base revenues increased 9%, which was aided by a 3% favorable FX impact.
 - CLAR revenues increased 3.6% y/y to \$171 MM, slightly lower than our estimate of \$173 MM and \$3 MM higher than consensus of \$168 MM. Operationally, revenues increased 9% and was offset by a negative 5% FX impact.
 - APAC revenues increased 1.2% y/y to \$167 MM, which was ~\$5 MM lower than our estimate of \$172 MM and in line with SA consensus of \$166 MM. Operationally, revenues increased 7% and was offset by a 6% FX impact.
- EPS in line; margins expand, but not meaningfully. Adjusted EPS of \$0.34 was in line with our estimate and consensus of \$0.34. Adjusted EPS excluded the net impact of \$41 MM or \$0.08 related to purchase accounting adjustments, acquisition costs and other one-time items. Gross margin of 65.28% was 53 bps higher than our estimate of 64.75%. Adjusted operating income increased ~10% y/y to \$273 MM, which was in line with our estimate of \$275 MM, while adjusted operating margin increased 31 bps y/y to 24.75%, which was 94 bps lower than our estimate of 25.69%. Lower operating margin versus our estimate was primarily attributable to higher than expected SG&A, which grew ~9% y/y.
- FY13 guidance narrowed. ZTS raised the low end of its revenue and EPS guidance ranges. Revenues are now expected to be \$4.475-\$4.525 billion vs. the prior range of \$4.425-\$4.525 billion and adjusted EPS guidance is expected to be \$1.38-\$1.42 from the prior range of \$1.36-\$1.42.

COMPANY DESCRIPTION

Zoetis is the leading global manufacturer of animal health medications and vaccines.

PRICE: US\$31.93 TARGET: US\$39.00 (24.5x FY14E EPS)

Kevin K. Ellich

Sr Research Analyst, Piper Jaffray & Co. 612 303-5666, kevin.k.ellich@pjc.com

Bradley D. Maiers

Research Analyst, Piper Jaffray & Co. 612 303-6646, bradley.d.maiers@pjc.com


Related Companies:

Share Price: 31.93

RISKS TO ACHIEVEMENT OF PRICE TARGET

Risks include increased regulatory pressures, adverse weather conditions, lower utilization of products, increased competition, and macro economic factors.

Price Performance - 1 Year




Source: Bloomberg

Piper Jaffray does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decisions. This report should be read in conjunction with important disclosure information, including an attestation under Regulation Analyst certification, found on pages 2 - 3 of this report or at the following site: http://www.piperjaffray.com/researchdisclosures

Zoetis Inc.
Page 1 of 258

IMPORTANT RESEARCH DISCLOSURES



Notes: The boxes on the Rating and Price Target History chart above indicate the date of the Research Note, the rating, and the price target. Each box represents a date on which an analyst made a change to a rating or price target, except for the first box, which may only represent the first Note written during the past three years.

Legend:

I: Initiating Coverage

R: Resuming Coverage

T: Transferring Coverage

D: Discontinuing Coverage

S: Suspending Coverage

OW: Overweight

N: Neutral

UW: Underweight NA: Not Available UR: Under Review

Distribution of Ratings/IB Services Piper Jaffray				
			IB Serv./Past 12 Mos.	
Rating	Count	Percent	Count	Percent
BUY [OW]	337	56.83	75	22.26
HOLD [N]	230	38.79	15	6.52
SELL [UW]	26	4.38	0	0.00

Note: Distribution of Ratings/IB Services shows the number of companies currently in each rating category from which Piper Jaffray and its affiliates received compensation for investment banking services within the past 12 months. FINRA rules require disclosure of which ratings most closely correspond with "buy," "hold," and "sell" recommendations. Piper Jaffray ratings are not the equivalent of buy, hold or sell, but instead represent recommended relative weightings. Nevertheless, Overweight corresponds most closely with buy, Neutral with hold and Underweight with sell. See Stock Rating definitions below.

Analyst Certification — Kevin K. Ellich, Sr Research Analyst — Bradley D. Maiers, Research Analyst

The views expressed in this report accurately reflect my personal views about the subject company and the subject security. In addition, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report.

Zoetis Inc.
Page 2 of 259



Research Disclosures

Piper Jaffray was making a market in the securities of Zoetis Inc. at the time this research report was published. Piper Jaffray will buy and sell Zoetis Inc. securities on a principal basis.

Piper Jaffray has received compensation for investment banking services from or has had a client relationship with Zoetis Inc. within the past 12 months.

Within the past 12 months Piper Jaffray was a managing underwriter of a public offering of, or dealer manager of a tender offer for, the securities of Zoetis Inc. or the securities of an affiliate.

Within the past 3 years Piper Jaffray participated in a public offering of, or acted as a dealer manager for, Zoetis Inc. securities.

Piper Jaffray research analysts receive compensation that is based, in part, on overall firm revenues, which include investment banking revenues.

Rating Definitions

Stock Ratings: Piper Jaffray ratings are indicators of expected total return (price appreciation plus dividend) within the next 12 months. At times analysts may specify a different investment horizon or may include additional investment time horizons for specific stocks. Stock performance is measured relative to the group of stocks covered by each analyst. Lists of the stocks covered by each are available at www.piperjaffray.com/ researchdisclosures. Stock ratings and/or stock coverage may be suspended from time to time in the event that there is no active analyst opinion or analyst coverage, but the opinion or coverage is expected to resume. Research reports and ratings should not be relied upon as individual investment advice. As always, an investor's decision to buy or sell a security must depend on individual circumstances, including existing holdings, time horizons and risk tolerance. Piper Jaffray sales and trading personnel may provide written or oral commentary, trade ideas, or other information about a particular stock to clients or internal trading desks reflecting different opinions than those expressed by the research analyst. In addition, Piper Jaffray technical research products are based on different methodologies and may contradict the opinions contained in fundamental research reports.

- Overweight (OW): Anticipated to outperform relative to the median of the group of stocks covered by the analyst.
- Neutral (N): Anticipated to perform in line relative to the median of the group of stocks covered by the analyst.
- Underweight (UW): Anticipated to underperform relative to the median of the group of stocks covered by the analyst.

Other Important Information

The material regarding the subject company is based on data obtained from sources we deem to be reliable; it is not guaranteed as to accuracy and does not purport to be complete. This report is solely for informational purposes and is not intended to be used as the primary basis of investment decisions. Piper Jaffray has not assessed the suitability of the subject company for any person. Because of individual client requirements, it is not, and it should not be construed as, advice designed to meet the particular investment needs of any investor. This report is not an offer or the solicitation of an offer to sell or buy any security. Unless otherwise noted, the price of a security mentioned in this report is the market closing price as of the end of the prior business day. Piper Jaffray does not maintain a predetermined schedule for publication of research and will not necessarily update this report. Piper Jaffray policy generally prohibits research analysts from sending draft research reports to subject companies; however, it should be presumed that the analyst(s) who authored this report has had discussions with the subject company to ensure factual accuracy prior to publication, and has had assistance from the company in conducting diligence, including visits to company sites and meetings with company management and other representatives.

Notice to customers: This material is not directed to, or intended for distribution to or use by, any person or entity if Piper Jaffray is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to such person or entity. Customers in any of the jurisdictions where Piper Jaffray and its affiliates do business who wish to effect a transaction in the securities discussed in this report should contact their local Piper Jaffray representative. Europe: This material is for the use of intended recipients only and only for distribution to professional and institutional investors, i.e. persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom, or persons who have been categorised by Piper Jaffray Ltd. as professional clients under the rules of the Financial Conduct Authority. United States: This report is distributed in the United States by Piper Jaffray & Co., member SIPC, FINRA and NYSE, Inc., which accepts responsibility for its contents. The securities described in this report may not have been registered under the U.S. Securities Act of 1933 and, in such case, may not be offered or sold in the United States or to U.S. persons unless they have been so registered, or an exemption from the registration requirements is available.

This report is produced for the use of Piper Jaffray customers and may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose without the prior consent of Piper Jaffray & Co. Additional information is available upon request.

Copyright 2013 Piper Jaffray. All rights reserved.

Zoetis Inc. Page 3 of 260